No IPO, but another $325 million for German innovator

9 July 2019

An outsized series B funding round will surely nix rumors that Europe’s largest privately-held biotech is about to list on the Nasdaq.

Mainz, Germany-based BioNTech, a specialist in oncology that is developing a highly personalized approach to treating cancer, has raised another $325 million from private sources.

One of the largest ever fundraising rounds for a European biotechnology company, the new money comes hot on the heels of a series A financing of $270 million last year. The firm has now raised a total of well over a billion dollars since it was founded in 2008.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK